Supernus awards Frank Mottola 100,000-share stock grant

The award’s vesting schedule is tied to the merger closing and extends through the fourth anniversary of that closing.

Available on EDGAR 11/02/2026 - 04:16 PM EST Accepted by SEC EDGAR 11/02/2026 - 04:15 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Supernus Pharmaceuticals, Inc. (SUPN) reported a direct award to SVP, Chief Tech. Ops. Officer Frank Mottola of 100,000 restricted stock units on October 30, 2026. The RSUs settle in common stock upon vesting: 40% vest when the merger-of-equals transaction with Indivior Pharmaceuticals, Inc. closes, followed by 15% on each of the first, second, third and fourth anniversaries of closing.

Insider Trade Summary

Grant/Award: 100,000 shares

Grant/Award 1 txn

Insider Mottola Frank

Role SVP, Chief Tech. Ops. Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Unit F1	100,000	$0.00	$0.00

Holdings After Transaction: Restricted Stock Unit — 100,000 contracts (Direct)

Holdings Before and After: Restricted Stock Unit, 0 to 100,000 contracts (Direct)

Footnotes (1)

1. F1. These restricted stock units ("RSUs") are settled in common stock upon vesting, which occurs in four installments. 40% of the RSUs vest upon the closing of the merger-of-equals transaction between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. (the "Closing"). 15% of the RSUs vest upon the one-year anniversary of the Closing. 15% of the RSUs vest upon the two-year anniversary of the Closing. 15% of the RSUs vest upon the three-year anniversary of the Closing. 15% of the RSUs vest upon the four-year anniversary of the Closing.

Key Figures

Restricted stock units awarded: 100,000 RSUs Initial vesting installment: 40% Subsequent vesting installments: 15% each

3 metrics

Restricted stock units awarded 100,000 RSUs Direct award to Frank Mottola on October 30, 2026

Initial vesting installment 40% Upon closing of the merger-of-equals transaction

Subsequent vesting installments 15% each On each of the first through fourth anniversaries of closing

Key Terms

restricted stock units, vesting, merger-of-equals transaction

3 terms

restricted stock units financial

"These restricted stock units ("RSUs") are settled in common stock upon vesting"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

vesting financial

"settled in common stock upon vesting"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

merger-of-equals transaction financial

"merger-of-equals transaction between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many RSUs did SUPN's SVP receive?

Frank Mottola received 100,000 restricted stock units in a direct award on October 30, 2026.

When do Frank Mottola’s SUPN RSUs vest?

40% vest upon closing of the merger-of-equals transaction between Supernus Pharmaceuticals and Indivior Pharmaceuticals. The remaining portions vest in four installments of 15% each, on the first through fourth anniversaries of closing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mottola Frank

(Last) (First) (Middle)

C/O SUPERNUS PHARMACEUTICALS, INC.,

9715 KEY WEST AVENUE

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
SUPERNUS PHARMACEUTICALS, INC. [ SUPN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Tech. Ops. Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	$0	10/30/2026		A		100,000		(1)	(1)	Common Stock	100,000	$0	100,000	D

Explanation of Responses:

1. These restricted stock units ("RSUs") are settled in common stock upon vesting, which occurs in four installments. 40% of the RSUs vest upon the closing of the merger-of-equals transaction between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. (the "Closing"). 15% of the RSUs vest upon the one-year anniversary of the Closing. 15% of the RSUs vest upon the two-year anniversary of the Closing. 15% of the RSUs vest upon the three-year anniversary of the Closing. 15% of the RSUs vest upon the four-year anniversary of the Closing.

Remarks:

	/s/ Timothy C. Dec, as attorney-in-fact	11/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)